We're so glad you're here! This site is to help anyone diagnosed with Medullary Thyroid Cancer and their caregivers find valuable information and support. If you'd like to connect with others with MTC, please consider joining our very active Facebook Group. You don't have to go through this alone!
If you don't yet have a copy, please download the American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma, aka "The Guidelines." This is the MTC Bible. Read it and know it and it will help you and your doctor ensure you get the proper treatment.
Lastly, please consider looking into being seen by an MTC expert. We do our best to keep a running list of what we call "Centers of Excellence." These are doctors and facilities that are properly trained and experienced enough to treat MTC patients. It's one of the most important decisions you can make on your journey.
"RET Alterations: A Rare but Actionable Oncogenic Driver · Moving Beyond Multi-Kinase Therapy: Selective RET Inhibition · Selpercatinib - Phase III Data ..."
"While management characterized the franchise as plateauing, they stressed that GAVRETO remains a dependable recurring revenue stream within the ..."
"RET fusion lung cancer developed rare RET insertion after pralsetinib resistance; switching to selpercatinib achieved partial response."
"After Tmunity sold to Gilead in 2023, Westlake's founding managing director and Tmunity chair Beth Seidenberg asked him to incubate a new biotech."
"Commercial performance and portfolio expansion. Commercial portfolio includes TAVALISSE, GAVRETO, and REZLIDHIA, each showing strong year-over-year ..."
This website is intended for educational purposes only. It is not intended, nor should it be interpreted, as medical advice or instructions of any kind. Readers are advised to consult their own medical doctor(s) for all matters involving their health and medical care.